Draft revised consolidated 3-year work plan for the Methodology Working Party (MWP)
Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms, Date of authorisation: 17/07/2015, Revision: 54, Status: Authorised
Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Hypertension, Date of authorisation: 16/10/1998, Revision: 47, Status: Authorised
Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Lymphoma, Follicular;Lymphoma, Large B-Cell, Diffuse, Date of authorisation: 23/08/2018, Revision: 12, Status: Authorised
Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 41, Status: Authorised
Human medicines European public assessment report (EPAR): Xofigo, radium Ra223 dichloride, Prostatic Neoplasms, Date of authorisation: 13/11/2013, Revision: 14, Status: Authorised
Tecvayli : EPAR - Product Information
Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate,umeclidinium,vilanterol, Pulmonary Disease, Chronic Obstructive, Date of authorisation: 15/11/2017, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Raxone, idebenone, Optic Atrophy, Hereditary, Leber, Date of authorisation: 08/09/2015, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms, Date of authorisation: 19/06/2015, Revision: 56, Status: Authorised